 Gossamer Bio, Inc.s lead candidate - Seralutinib, indicated for Pulmonary Arterial Hypertension - met its primary endpoint in the Phase 2 TORREY study. Nevertheless, investors dumped the stock - due to Seralutinibs perceived inferiority to Mercks Sotatercept. 